Naslov
Recombinant factor VIIa treatment in children with end-stage liver disease

Autori
Popović, Ljiljana ; Župančić, Božidar ; Meštrović, Tomislav

Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), ostalo

Izvornik
Abstract CD / - , 2004

Skup
World Congress of pediatric Surgery

Mjesto i datum
Zagreb, Hrvatska, 22.06.2004. - 27.06.2004

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
recombinant factor VIIa

Sažetak
Background: We report the use of recombinant activated factor VII (rFVIIa, Novoseven, NovoNordisk) to control coagulation disorders and massive hemorrhage in children with end-stage liver disease. Methods and Results: Nine children, ages ranged from 9 months to 14 years, with end-stage liver disease, were treated with rFVIIa before and/or during orthotopic liver transplantation. Baseline coagulation function included all coagulation-related parameters, as well as prothrombin time (PT) of 48.17 ± ; 12.41% activity of normal plasma and activated partial thromboplastin time (APTT) of 81.42 ± ; 29.64 seconds. Recombinant factor VIIa was administered intravenously in the dose of 90 µ ; g/kg bw. One to two doses were used in 8 children, three doses only in one child (every 2 hours). At 40 minutes after rFVIIa administration, PT and APTT significantly improved (PT 104.92 ± ; 12.81% activity of normal plasma, APTT 39.27 ± ; 2.66 ; p < 0.05, T-test for dependent samples). Conclusion: When conventional therapy fails to correct the coagulopathy, rFVIIa provides a rapid and successful correction of coagulation disturbance in children with end-stage liver disease. No thromboembolic events occurred in our patients during the perioperative period.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA